Neurodevelopmental outcome after antenatal therapy for fetal supraventricular tachyarrhythmia: 3‐year follow‐up of multicenter trial

Although many studies have supported the efficacy of transplacental treatment for fetal supraventricular tachyarrhythmia, the long‐term neurodevelopmental outcome after antenatal antiarrhythmic treatment is not well understood. The aim of this study was to investigate the prognosis and neurodevelopmental outcome at 36 months of corrected age and the incidence of tachyarrhythmia after birth, following protocol‐defined antenatal therapy for fetal supraventricular tachyarrhythmia.

[1]  A. Marelli,et al.  Neurocognitive disorders amongst patients with congenital heart disease undergoing procedures in childhood. , 2021, International journal of cardiology.

[2]  O. Aljohani,et al.  Antiarrhythmic Treatment Duration and Tachycardia Recurrence in Infants with Supraventricular Tachycardia , 2021, Pediatric Cardiology.

[3]  H. Sago,et al.  Neurodevelopmental impairment at 3 years of age after fetoscopic laser surgery for twin‐to‐twin transfusion syndrome , 2020, Prenatal diagnosis.

[4]  Vassilios J. Bezzerides,et al.  Low mortality in fetal supraventricular tachycardia: Outcomes in a 30‐year single‐institution experience , 2020, Journal of cardiovascular electrophysiology.

[5]  W. Shimizu,et al.  Antenatal Therapy for Fetal Supraventricular Tachyarrhythmias: Multicenter Trial. , 2019, Journal of the American College of Cardiology.

[6]  G. Yildirim,et al.  Flecainide as first-line treatment for fetal supraventricular tachycardia , 2018, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[7]  Fares Alahdab,et al.  First‐Line Antiarrhythmic Transplacental Treatment for Fetal Tachyarrhythmia: A Systematic Review and Meta‐Analysis , 2017, Journal of the American Heart Association.

[8]  G. Hill,et al.  Transplacental treatment of fetal tachycardia: A systematic review and meta‐analysis , 2017, Prenatal diagnosis.

[9]  W. Shimizu,et al.  Antenatal antiarrhythmic treatment for fetal tachyarrhythmias: a study protocol for a prospective multicentre trial , 2017, BMJ Open.

[10]  J. Marek,et al.  Flecainide versus digoxin for fetal supraventricular tachycardia: Comparison of two drug treatment protocols. , 2016, Heart rhythm.

[11]  U. Gembruch,et al.  High-dose flecainide is the most effective treatment of fetal supraventricular tachycardia. , 2016, Heart rhythm.

[12]  Y. Ohya,et al.  Comparison of the Kyoto Scale of Psychological Development 2001 with the parent-rated Kinder Infant Development Scale (KIDS) , 2016, Brain and Development.

[13]  O. Iwata,et al.  Developmental assessment of VLBW infants at 18months of age: A comparison study between KSPD and Bayley III , 2016, Brain and Development.

[14]  J. Rychik,et al.  Diagnosis and Treatment of Fetal Cardiac Disease: A Scientific Statement From the American Heart Association , 2014, Circulation.

[15]  John O. Willis,et al.  Wechsler Intelligence Scale for Children–Fourth Edition , 2014 .

[16]  A. Khalil,et al.  Brain abnormalities and neurodevelopmental delay in congenital heart disease: systematic review and meta‐analysis , 2014, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[17]  H. Won,et al.  Molecular genetic, cardiac and neurodevelopmental findings in cases of prenatally diagnosed rhabdomyoma associated with tuberous sclerosis complex , 2013, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[18]  F. Walther,et al.  Long-term neurodevelopmental outcome after intrauterine transfusion for hemolytic disease of the fetus/newborn: the LOTUS study. , 2012, American journal of obstetrics and gynecology.

[19]  S. Moodley,et al.  Postnatal Outcome in Patients With Fetal Tachycardia , 2012, Pediatric Cardiology.

[20]  Greg Ryan,et al.  Comparison of Transplacental Treatment of Fetal Supraventricular Tachyarrhythmias With Digoxin, Flecainide, and Sotalol: Results of a Nonrandomized Multicenter Study , 2011, Circulation.

[21]  Nicolas Guizard,et al.  Brain Volume and Metabolism in Fetuses With Congenital Heart Disease: Evaluation With Quantitative Magnetic Resonance Imaging and Spectroscopy , 2010, Circulation.

[22]  N. Blom,et al.  Long-term neurodevelopmental outcome after fetal arrhythmia. , 2009, American journal of obstetrics and gynecology.

[23]  E. Jaeggi,et al.  Neonatal supraventricular tachycardia: outcomes over a 27‐year period at a single institution , 2008, Acta paediatrica.

[24]  A. Ghidini,et al.  Fetal arrhythmias: natural history and management. , 2005, Ultrasound in medicine & biology.

[25]  L. D. de Vries,et al.  Neurological outcome of children who were treated for fetal tachycardia complicated by hydrops , 2004, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[26]  S. Andersson,et al.  Long‐Term Outcome in Fetuses With Cardiac Arrhythmias , 2003, Obstetrics and gynecology.

[27]  R. Friedman,et al.  Frequency of recurrence among infants with supraventricular tachycardia and comparison of recurrence rates among those with and without preexcitation and among those with and without response to digoxin and/or propranolol therapy. , 2003, The American journal of cardiology.

[28]  J. Simpson,et al.  Review of diagnosis, treatment, and outcome of fetal atrial flutter compared with supraventricular tachycardia , 2003, Heart.

[29]  C. Cans.  Surveillance of cerebral palsy in Europe: a collaboration of cerebral palsy surveys and registers , 2000, Developmental medicine and child neurology.

[30]  B. Cuneo,et al.  Management Strategy for Fetal Tachycardia , 2000, Obstetrics and gynecology.

[31]  G. Visser,et al.  Sotalol in the treatment of fetal dysrhythmias. , 2000, Circulation.

[32]  L. D. de Vries,et al.  Neurological morbidity after fetal supraventricular tachyarrhythmia , 1999, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[33]  M. Miyajima,et al.  [Causative factors resulting in intractability of congenital hydrocephalus--analysis of psychomotor development and MRI findings of the brain in sixteen congenitally hydrocephalic patients]. , 1997, No to hattatsu = Brain and development.

[34]  S. Arulkumaran,et al.  Management of non‐immune hydrops: 8 years' experience , 1996, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[35]  S. Gidding,et al.  Fetal tachycardia: mechanisms and predictors of hydrops fetalis. , 1996, Journal of the American College of Cardiology.